We choose: Adolescent girls and young women’s choice for an HIV prevention product in a cross-over randomized clinical trial conducted in South Africa, Uganda, and Zimbabwe
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0308577 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift PLOS ONE, 2024. Verfasst von Millicent Atujuna und 10 weiteren Autor:innen. Beteiligte Einrichtung: Desmond Tutu HIV Centre, Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, Cape Town, South Africa. Hauptthemen laut MEDLINE: HIV Infections, Cross-Over Studies, Pre-Exposure Prophylaxis, Anti-HIV Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
With new pre-exposure prophylaxis (PrEP) modalities for HIV prevention becoming available, understanding how adolescent girls and young women (AGYW) navigate through PrEP options is essential, including factors underlying their choice. Through 16 focus group discussions (FGDs) and 52 in-depth interviews (IDIs) from REACH, an open-label crossover study in which AGYW were allocated 1:1 (between 06 February 2019 and 18 March 2020) to receive oral PrEP for six months and the dapivirine ring for six months, in a randomized sequence, followed by a 6-month period where either product (or neither) could be chosen, we explored decision-making process and product choice, using a mixed inductive-deductive analytical approach. Key themes included the desire to remain HIV-negative and weighing product attributes through experiential learning. Product triability appeared important in informing product choice as individual circumstances changed or assuaging side effects with a given product. Approved biomedical prevention innovations may also benefit from hands-on experience to help with adoption and use during real-world implementation. Furthermore, support from trusted providers will remain critical as AGYW contemplate navigating through PrEP options and choice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Desmond Tutu HIV Centre, Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, Cape Town, South Africa.
- RTI International, Research Triangle Park, NC, United States of America.
- WITS Reproductive Health and HIV Institute (WRHI), Johannesburg, South Africa.
- University of Zimbabwe Clinical Trials Research Centre (UZ-CRC), Harare, Zimbabwe.
- School of Public Health, Jomo Kenyatta University of Agriculture and Technology, Nairobi, Kenya.
- Department of Global Health, University of Washington, Seattle, WA, United States of America.
ORCID-Profile: Millicent Atujuna, Sarah T Roberts, Ariane van der Straten
Förderung
- NIAID NIH HHS
- National Institute of Allergy and Infectious Diseases
Zitieren
APA
Atujuna, M., Williams, K., Roberts, S. T., Young, A., Browne, E. N., Mangxilana, N. T., Tenza, S., Shapley-Quinn, M. K., Tauya, T., Ngure, K., & van der Straten, A. (2024). We choose: Adolescent girls and young women’s choice for an HIV prevention product in a cross-over randomized clinical trial conducted in South Africa, Uganda, and Zimbabwe. PLOS ONE. https://doi.org/10.1371/journal.pone.0308577
Vancouver
Atujuna M, Williams K, Roberts ST, Young A, Browne EN, Mangxilana NT, et al. We choose: Adolescent girls and young women’s choice for an HIV prevention product in a cross-over randomized clinical trial conducted in South Africa, Uganda, and Zimbabwe. PLOS ONE. 2024. doi:10.1371/journal.pone.0308577
BibTeX
@article{Atujuna2024,
author = {Atujuna, Millicent and Williams, Kristin and Roberts, Sarah T and Young, Alinda and Browne, Erica N and Mangxilana, Nomvuyo T and Tenza, Siyanda and Shapley-Quinn, Mary Kate and Tauya, Thelma and Ngure, Kenneth and van der Straten, Ariane},
title = {We choose: Adolescent girls and young women’s choice for an HIV prevention product in a cross-over randomized clinical trial conducted in South Africa, Uganda, and Zimbabwe},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0308577}
}
EUVIMED